#BEGIN_DRUGCARD DB01119

# AHFS_Codes:
24:08.20

# ATC_Codes:
C02DA01
V03AH01

# Absorption:
Readily absorbed following oral administration.

# Biotransformation:
Hepatic.

# Brand_Mixtures:
Not Available

# Brand_Names:
Dizoxide
Eudemine
Hyperstat
Hypertonalum
Mutabase
Proglicem
Proglycem

# CAS_Registry_Number:
364-98-7

# ChEBI_ID:
4495

# Chemical_Formula:
C8H7ClN2O2S

# Chemical_IUPAC_Name:
7-chloro-3-methyl-4H-1$l^{6},2,4-benzothiadiazine-1,1-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
503347

# Description:
A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. [PubChem]

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Antihypertensive Agents
Diuretics, Thiazide
Vasodilator Agents

# Drug_Interactions:
Bendroflumethiazide	Significant hyperglycemic effect
Chlorpropamide	Antagonism.
Chlorthalidone	Significant hyperglycemic effect
Fosphenytoin	Diazoxide decreases the hydantoin effect
Glyburide	Antagonism.
Hydrochlorothiazide	Significant hyperglycemic effect
Indapamide	Significant hyperglycemic effect
Phenytoin	Diazoxide decreases the efficacy of phenytoin.
Trandolapril	Diazoxide may increase the hypotensive effect of Trandolapril. Monitor for changes in blood pressure.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.20

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
2850 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Diazoxide

# HET_ID:
Not Available

# Half_Life:
28 &plusmn;8.3 hours in normal adults.

# InChI_Identifier:
InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)

# InChI_Key:
InChIKey=GDLBFKVLRPITMI-UHFFFAOYSA-N

# Indication:
Used parentally to treat hypertensive emergencies. Also used to treat hypoglycemia secondary to insulinoma.

# KEGG_Compound_ID:
C06949

# KEGG_Drug_ID:
D00294

# LIMS_Drug_ID:
1119

# Mechanism_Of_Action:
As a diuretic, diazoxide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like diazoxide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of diazoxide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. As a antihypoglycemic, diazoxide inhibits insulin release from the pancreas, probably by opening potassium channels in the beta cell membrane.

# Melting_Point:
330.5 Â°C

# Molecular_Weight_Avg:
230.671

# Molecular_Weight_Mono:
229.991675875

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449285

# Pharmacology:
Diazoxide is a potassium channel activator, which causes local relaxation in smooth muscle by increasing membrane permeability to potassium ions. This switches off voltage-gated calcium ion channels which inhibits the generation of an action potential.

# Predicted_LogP_Hydrophobicity:
1.09

# Predicted_LogS:
-2.6

# Predicted_Water_Solubility:
5.52e-01 g/l

# Primary_Accession_No:
DB01119

# Protein_Binding:
Very high (more than 90%) to serum proteins.

# PubChem_Compound_ID:
3019

# PubChem_Substance_ID:
46508027

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00914

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Oral LD<sub>50</sub> in rat and mouse: 980 mg/kg and 444 mg/kg, respectively.

# Update_Date:
2013-02-08 16:19:55 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Diazoxide

# pKa_Isoelectric_Point:
8.74

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
GLUL

# Phase_1_Metabolizing_Enzyme_1_ID:
3987

# Phase_1_Metabolizing_Enzyme_1_Name:
Glutamine synthetase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Glutamine synthetase
MTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSEPKCVEELPEW
NFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVFKYNRRPAETNLRHTCKRI
MDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRDIVEAHY
RACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILHRVCEDFGVIATFDP
KPIPGNWNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDPKGGLDNARRL
TGFHETSNINDFSAGVANRSASIRIPRTVGQEKKGYFEDRRPSANCDPFSVTEALIRTCL
LNETGDEPFQYKN

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P15104

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10518593	D'hahan N, Moreau C, Prost AL, Jacquet H, Alekseev AE, Terzic A, Vivaudou M: Pharmacological plasticity of cardiac ATP-sensitive potassium channels toward diazoxide revealed by ADP. Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12162-7.
10581306	Sakura H, Trapp S, Liss B, Ashcroft FM: Altered functional properties of KATP channel conferred by a novel splice variant of SUR1. J Physiol. 1999 Dec 1;521 Pt 2:337-50.
10604939	Shindo T, Katayama Y, Horio Y, Kurachi Y: MCC-134, a novel vascular relaxing agent, is an inverse agonist for the pancreatic-type ATP-sensitive K(+) channel. J Pharmacol Exp Ther. 2000 Jan;292(1):131-5.
11808879	de Lonlay P, Fournet JC, Touati G, Groos MS, Martin D, Sevin C, Delagne V, Mayaud C, Chigot V, Sempoux C, Brusset MC, Laborde K, Bellane-Chantelot C, Vassault A, Rahier J, Junien C, Brunelle F, Nihoul-Fekete C, Saudubray JM, Robert JJ: Heterogeneity of persistent hyperinsulinaemic hypoglycaemia. A series of 175 cases. Eur J Pediatr. 2002 Jan;161(1):37-48.
12770942	Russ U, Lange U, Loffler-Walz C, Hambrock A, Quast U: Binding and effect of K ATP channel openers in the absence of Mg2+. Br J Pharmacol. 2003 May;139(2):368-80.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
KCNJ11

# Drug_Target_1_GenBank_ID_Gene:
D50582

# Drug_Target_1_GenBank_ID_Protein:
1088445

# Drug_Target_1_GeneCard_ID:
KCNJ11

# Drug_Target_1_Gene_Name:
KCNJ11

# Drug_Target_1_Gene_Sequence:
>1173 bp
ATGCTGTCCCGCAAGGGCATCATCCCCGAGGAATACGTGCTGACACGCCTGGCAGAGGAC
CCTGCCGAGCCCAGGTACCGTGCCCGCCAGCGGAGGGCCCGCTTTGTGTCCAAGAAAGGC
AACTGCAACGTGGCCCACAAGAACATCCGGGAGCAGGGCCGCTTCCTGCAGGACGTGTTC
ACCACGCTGGTGGACCTCAAGTGGCCACACACATTGCTCATCTTCACCATGTCCTTCCTG
TGCAGCTGGCTGCTCTTCGCCATGGCCTGGTGGCTCATCGCCTTCGCCCACGGTGACCTG
GCCCCCAGCGAGGGCACTGCTGAGCCCTGTGTCACCAGCATCCACTCCTTCTCGTCTGCC
TTCCTTTTCTCCATTGAGGTCCAAGTGACTATTGGCTTTGGGGGGCGCATGGTGACTGAG
GAGTGCCCACTGGCCATCCTGAGCCTCATCGTGCAGAACATCGTGGGGCTCATGATCAAC
GCCATCATGCTTGGCTGCATCTTCATGAAGACTGCCCAAGCCCACCGCAGGGCTGAGACC
CTCATCTTCAGCAAGCATGCGGTGATCGCTCTGCGCCACGGCCGCCTCTGCTTCATGCTA
CGTGTGGGTGACCTCCGCAAGAGCATGATCATCAGCGCCACCATCCACATGCAGGTGGTA
CGCAAGACCACCAGCCCCGAGGGCGAGGTGGTGCCCCTCCACCAGGTGGACATCCCCATG
GAGAACGGCGTGGGTGGCAACAGCATCTTCCTGGTGGCCCCGCTGATCATCTACCATGTC
ATTGATGCCAACAGCCCACTCTACGACCTGGCACCCAGCGACCTGCACCACCACCAGGAC
CTCGAGATCATCGTCATCCTGGAAGGCGTGGTGGAAACCACGGGCATCACCACCCAGGCC
CGCACCTCCTACCTGGCCGATGAGATCCTGTGGGGCCAGCGCTTTGTGCCCATTGTAGCT
GAGGAGGACGGACGTTACTCTGTGGACTACTCCAAGTTTGGCAACACCATCAAAGTGCCC
ACACCACTCTGCACGGCCCGCCAGCTTGATGAGGACCACAGCCTACTGGAAGCTCTGACC
CTCGCCTCAGCCCGCGGGCCCCTGCGCAAGCGCAGCGTGCCCATGGCCAAGGCCAAGCCC
AAGTTCAGCATCTCTCCAGATTCCCTGTCCTGA

# Drug_Target_1_General_Function:
Involved in inward rectifier potassium channel activity

# Drug_Target_1_General_References:
10204114	Aguilar-Bryan L, Bryan J: Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev. 1999 Apr;20(2):101-35.
10338089	Meissner T, Beinbrech B, Mayatepek E: Congenital hyperinsulinism: molecular basis of a heterogeneous disease. Hum Mutat. 1999;13(5):351-61.
10391210	Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet. 1999 Jul;22(3):239-47.
7502040	Inagaki N, Gonoi T, Clement JP 4th, Namba N, Inazawa J, Gonzalez G, Aguilar-Bryan L, Seino S, Bryan J: Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science. 1995 Nov 17;270(5239):1166-70.
7847376	Thomas PM, Cote GJ, Hallman DM, Mathew PM: Homozygosity mapping, to chromosome 11p, of the gene for familial persistent hyperinsulinemic hypoglycemia of infancy. Am J Hum Genet. 1995 Feb;56(2):416-21.
8897013	Sakura H, Wat N, Horton V, Millns H, Turner RC, Ashcroft FM: Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia. 1996 Oct;39(10):1233-6.
9032109	Inoue H, Ferrer J, Warren-Perry M, Zhang Y, Millns H, Turner RC, Elbein SC, Hampe CL, Suarez BK, Inagaki N, Seino S, Permutt MA: Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. Diabetes. 1997 Mar;46(3):502-7.

# Drug_Target_1_HGNC_ID:
HGNC:6257

# Drug_Target_1_HPRD_ID:
09022

# Drug_Target_1_ID:
781

# Drug_Target_1_Locus:
11p15.1

# Drug_Target_1_Molecular_Weight:
43541

# Drug_Target_1_Name:
ATP-sensitive inward rectifier potassium channel 11

# Drug_Target_1_Number_of_Residues:
390

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Amlodipine Pathway	SMP00376
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Disopyramide Pathway	SMP00325
Enalapril Pathway	SMP00148
Felodipine Pathway	SMP00377
Flecainide Pathway	SMP00331
Fosinopril Pathway	SMP00149
Fosphenytoin (Antiarrhythmic) Pathway	SMP00326
Ibutilide Pathway	SMP00332
Isradipine Pathway	SMP00378
Lidocaine (Antiarrhythmic) Pathway	SMP00328
Lisinopril Pathway	SMP00150
Mexiletine Pathway	SMP00329
Moexipril Pathway	SMP00151
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Perindopril Pathway	SMP00152
Phenytoin (Antiarrhythmic) Pathway	SMP00327
Procainamide (Antiarrhythmic) Pathway	SMP00324
Quinapril Pathway	SMP00153
Quinidine Pathway	SMP00323
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Tocainide Pathway	SMP00330
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_1_Pfam_Domain_Function:
PF01007	IRK

# Drug_Target_1_Protein_Sequence:
>ATP-sensitive inward rectifier potassium channel 11
MLSRKGIIPEEYVLTRLAEDPAEPRYRARQRRARFVSKKGNCNVAHKNIREQGRFLQDVF
TTLVDLKWPHTLLIFTMSFLCSWLLFAMAWWLIAFAHGDLAPSEGTAEPCVTSIHSFSSA
FLFSIEVQVTIGFGGRMVTEECPLAILILIVQNIVGLMINAIMLGCIFMKTAQAHRRAET
LIFSKHAVIALRHGRLCFMLRVGDLRKSMIISATIHMQVVRKTTSPEGEVVPLHQVDIPM
ENGVGGNSIFLVAPLIIYHVIDANSPLYDLAPSDLHHHQDLEIIVILEGVVETTGITTQA
RTSYLADEILWGQRFVPIVAEEDGRYSVDYSKFGNTIKVPTPLCTARQLDEDHSLLEALT
LASARGPLRKRSVPMAKAKPKFSISPDSLS

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium

# Drug_Target_1_SwissProt_ID:
Q14654

# Drug_Target_1_SwissProt_Name:
IRK11_HUMAN

# Drug_Target_1_Synonyms:
IKATP
Inward rectifier K(+) channel Kir6.2
Potassium channel, inwardly rectifying subfamily J member 11

# Drug_Target_1_Theoretical_pI:
8.10

# Drug_Target_1_Transmembrane_Regions:
69-93
145-166

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
15306243	Domoki F, Bari F, Nagy K, Busija DW, Siklos L: Diazoxide prevents mitochondrial swelling and Ca2+ accumulation in CA1 pyramidal cells after cerebral ischemia in newborn pigs. Brain Res. 2004 Sep 3;1019(1-2):97-104.
7585327	Erdemli G, Krnjevic K: Actions of diazoxide on CA1 neurons in hippocampal slices from rats. Can J Physiol Pharmacol. 1995 May;73(5):608-18.
7681475	Crepel V, Rovira C, Ben-Ari Y: The K+ channel opener diazoxide enhances glutamatergic currents and reduces GABAergic currents in hippocampal neurons. J Neurophysiol. 1993 Feb;69(2):494-503.
8298083	Erdemli G, Krnjevic K: Diazoxide suppresses slowly-inactivating outward and inward currents in CA1 hippocampal neurones. Neuroreport. 1993 Dec 13;5(3):249-51.
9439778	Scuvee-Moreau J, Seutin V, Vrijens B, Pirotte B, De Tullio P, Massotte L, Albert A, Delarge J, Dresse A: Effect of potassium channel openers on the firing rate of hippocampal pyramidal cells and A10 dopaminergic neurons in vitro. Arch Physiol Biochem. 1997 Sep;105(5):421-8.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
CA1

# Drug_Target_2_GenBank_ID_Gene:
X05014

# Drug_Target_2_GenBank_ID_Protein:
29600

# Drug_Target_2_GeneCard_ID:
CA1

# Drug_Target_2_Gene_Name:
CA1

# Drug_Target_2_Gene_Sequence:
>786 bp
ATGGCAAGTCCAGACTGGGGATATGATGACAAAAATGGTCCTGAACAATGGAGCAAGCTG
TATCCCATTGCCAATGGAAATAACCAATCCCCTGTTGATATTAAAACCAGTGAAACCAAA
CATGACACCTCTCTGAAACCTATTAGTGTCTCCTACAACCCAGCCACAGCCAAAGAAATT
ATCAATGTGGGGCATTCTTTCCATGTAAATTTTGAGGACAACGATAACCGATCAGTGCTG
AAAGGTGGTCCTTTCTCTGACAGCTACAGGCTCTTTCAGTTTCATTTTCACTGGGGCAGT
ACAAATGAGCATGGTTCAGAACATACAGTGGATGGAGTCAAATATTCTGCCGAGCTTCAC
GTAGCTCACTGGAATTCTGCAAAGTACTCCAGCCTTGCTGAAGCTGCCTCAAAGGCTGAT
GGTTTGGCAGTTATTGGTGTTTTGATGAAGGTTGGTGAGGCCAACCCAAAGCTGCAGAAA
GTACTTGATGCCCTCCAAGCAATTAAAACCAAGGGCAAACGAGCCCCATTCACAAATTTT
GACCCCTCTACTCTCCTTCCTTCATCCCTGGATTTCTGGACCTACCCTGGCTCTCTGACT
CATCCTCCTCTTTATGAGAGTGTAACTTGGATCATCTGTAAGGAGAGCATCAGTGTCAGC
TCAGAGCAGCTGGCACAATTCCGCAGCCTTCTATCAAATGTTGAAGGTGATAACGCTGTC
CCCATGCAGCACAACAACCGCCCAACCCAACCTCTGAAGGGCAGAACAGTGAGAGCTTCA
TTTTGA

# Drug_Target_2_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_2_General_References:
2121614	Lowe N, Brady HJ, Barlow JH, Sowden JC, Edwards M, Butterworth PH: Structure and methylation patterns of the gene encoding human carbonic anhydrase I. Gene. 1990 Sep 14;93(2):277-83.
3104879	Barlow JH, Lowe N, Edwards YH, Butterworth PH: Human carbonic anhydrase I cDNA. Nucleic Acids Res. 1987 Mar 11;15(5):2386.
4207120	Lin KT, Deutsch HF: Human carbonic anhydrases. XII. The complete primary structure of the C isozyme. J Biol Chem. 1974 Apr 25;249(8):2329-37.
4217196	Giraud N, Marriq C, Laurent-Tabusse G: [Primary structure of human B erythrocyte carbonic anhydrase. 3. Sequence of CNBr fragment I and III (residues 149-260)] Biochimie. 1974;56(8):1031-43.
4625868	Andersson B, Nyman PO, Strid L: Amino acid sequence of human erythrocyte carbonic anhydrase B. Biochem Biophys Res Commun. 1972 Aug 7;48(3):670-7.
4632246	Lin KT, Deutsch HF: Human carbonic anhydrases. XI. The complete primary structure of carbonic anhydrase B. J Biol Chem. 1973 Mar 25;248(6):1885-93.
6781336	Omoto K, Ueda S, Goriki K, Takahashi N, Misawa S, Pagaran IG: Population genetic studies of the Philippine Negritos. III. Identification of the carbonic anhydrase-1 variant with CA1 Guam. Am J Hum Genet. 1981 Jan;33(1):105-11.
7866410	Chegwidden WR, Wagner LE, Venta PJ, Bergenhem NC, Yu YS, Tashian RE: Marked zinc activation of ester hydrolysis by a mutation, 67-His (CAT) to Arg (CGT), in the active site of human carbonic anhydrase I. Hum Mutat. 1994;4(4):294-6.
804171	Kannan KK, Notstrand B, Fridborg K, Lovgren S, Ohlsson A, Petef M: Crystal structure of human erythrocyte carbonic anhydrase B. Three-dimensional structure at a nominal 2.2-A resolution. Proc Natl Acad Sci U S A. 1975 Jan;72(1):51-5.

# Drug_Target_2_HGNC_ID:
HGNC:1368

# Drug_Target_2_HPRD_ID:
00265

# Drug_Target_2_ID:
295

# Drug_Target_2_Locus:
8q13-q22.1

# Drug_Target_2_Molecular_Weight:
28739

# Drug_Target_2_Name:
Carbonic anhydrase 1

# Drug_Target_2_Number_of_Residues:
260

# Drug_Target_2_PDB_ID:
1CZM

# Drug_Target_2_Pathway:
Cimetidine Pathway	SMP00232
Esomeprazole Pathway	SMP00225
Famotidine Pathway	SMP00231
Lansoprazole Pathway	SMP00227
Nizatidine Pathway	SMP00233
Omeprazole Pathway	SMP00226
Pantoprazole Pathway	SMP00228
Pirenzepine Pathway	SMP00246
Rabeprazole Pathway	SMP00229
Ranitidine Pathway	SMP00230

# Drug_Target_2_Pfam_Domain_Function:
PF00194	Carb_anhydrase

# Drug_Target_2_Protein_Sequence:
>Carbonic anhydrase 1
ASPDWGYDDKNGPEQWSKLYPIANGNNQSPVDIKTSETKHDTSLKPISVSYNPATAKEII
NVGHSFHVNFEDNDNRSVLKGGPFSDSYRLFQFHFHWGSTNEHGSEHTVDGVKYSAELHV
AHWNSAKYSSLAEAASKADGLAVIGVLMKVGEANPKLQKVLDALQAIKTKGKRAPFTNFD
PSTLLPSSLDFWTYPGSLTHPPLYESVTWIICKESISVSSEQLAQFRSLLSNVEGDNAVP
MQHNNRPTQPLKGRTVRASF

# Drug_Target_2_Reaction:
H2CO3 = CO2 + H2O

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Reversible hydration of carbon dioxide

# Drug_Target_2_SwissProt_ID:
P00915

# Drug_Target_2_SwissProt_Name:
CAH1_HUMAN

# Drug_Target_2_Synonyms:
CA-I
Carbonate dehydratase I
Carbonic anhydrase I
EC 4.2.1.1

# Drug_Target_2_Theoretical_pI:
7.14

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasm

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
12511769	Munoz A, Nakazaki M, Goodman JC, Barrios R, Onetti CG, Bryan J, Aguilar-Bryan L: Ischemic preconditioning in the hippocampus of a knockout mouse lacking SUR1-based K(ATP) channels. Stroke. 2003 Jan;34(1):164-70.
8612523	Sekine N, Ullrich S, Regazzi R, Pralong WF, Wollheim CB: Postreceptor signalling of growth hormone and prolactin and their effects in the differentiated insulin-secreting cell line, INS-1. Endocrinology. 1996 May;137(5):1841-50.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
CA2

# Drug_Target_3_GenBank_ID_Gene:
M77181

# Drug_Target_3_GenBank_ID_Protein:
179780

# Drug_Target_3_GeneCard_ID:
CA2

# Drug_Target_3_Gene_Name:
CA2

# Drug_Target_3_Gene_Sequence:
>783 bp
ATGTCCCATCACTGGGGGTACGGCAAACACAACGGACCTGAGCACTGGCATAAGGACTTC
CCCATTGCCAAGGGAGAGCGCCAGTCCCCTGTTGACATCGACACTCATACAGCCAAGTAT
GACCCTTCCCTGAAGCCCCTGTCTGTTTCCTATGATCAAGCAACTTCCCTGAGGATCCTC
AACAATGGTCATGCTTTCAACGTGGAGTTTGATGACTCTCAGGACAAAGCAGTGCTCAAG
GGAGGACCCCTGGATGGCACTTACAGATTGATTCAGTTTCACTTTCACTGGGGTTCACTT
GATGGACAAGGTTCAGAGCATACTGTGGATAAAAAGAAATATGCTGCAGAACTTCACTTG
GTTCACTGGAACACCAAATATGGGGATTTTGGGAAAGCTGTGCAGCAACCTGATGGACTG
GCCGTTCTAGGTATTTTTTTGAAGGTTGGCAGCGCTAAACCGGGCCTTCAGAAAGTTGTT
GATGTGCTGGATTCCATTAAAACAAAGGGCAAGAGTGCTGACTTCACTAACTTCGATCCT
CGTGGCCTCCTTCCTGAATCCTTGGATTACTGGACCTACCCAGGCTCACTGACCACCCCT
CCTCTTCTGGAATGTGTGACCTGGATTGTGCTCAAGGAACCCATCAGCGTCAGCAGCGAG
CAGGTGTTGAAATTCCGTAAACTTAACTTCAATGGGGAGGGTGAACCCGAAGAACTGATG
GTGGACAACTGGCGCCCAGCTCAGCCACTGAAGAACAGGCAAATCAAAGCTTCCTTCAAA
TAA

# Drug_Target_3_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_3_General_References:
11076507	Cox JD, Hunt JA, Compher KM, Fierke CA, Christianson DW: Structural influence of hydrophobic core residues on metal binding and specificity in carbonic anhydrase II. Biochemistry. 2000 Nov 14;39(45):13687-94.
1542674	Roth DE, Venta PJ, Tashian RE, Sly WS: Molecular basis of human carbonic anhydrase II deficiency. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1804-8.
1928091	Venta PJ, Welty RJ, Johnson TM, Sly WS, Tashian RE: Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (107 His----Tyr): complete structure of the normal human CA II gene. Am J Hum Genet. 1991 Nov;49(5):1082-90.
3000449	Venta PJ, Montgomery JC, Hewett-Emmett D, Tashian RE: Comparison of the 5' regions of human and mouse carbonic anhydrase II genes and identification of possible regulatory elements. Biochim Biophys Acta. 1985 Dec 18;826(4):195-201.
3108857	Montgomery JC, Venta PJ, Tashian RE, Hewett-Emmett D: Nucleotide sequence of human liver carbonic anhydrase II cDNA. Nucleic Acids Res. 1987 Jun 11;15(11):4687.
3121496	Murakami H, Marelich GP, Grubb JH, Kyle JW, Sly WS: Cloning, expression, and sequence homologies of cDNA for human carbonic anhydrase II. Genomics. 1987 Oct;1(2):159-66.
3151019	Eriksson AE, Jones TA, Liljas A: Refined structure of human carbonic anhydrase II at 2.0 A resolution. Proteins. 1988;4(4):274-82.
3151020	Eriksson AE, Kylsten PM, Jones TA, Liljas A: Crystallographic studies of inhibitor binding sites in human carbonic anhydrase II: a pentacoordinated binding of the SCN- ion to the zinc at high pH. Proteins. 1988;4(4):283-93.
4207120	Lin KT, Deutsch HF: Human carbonic anhydrases. XII. The complete primary structure of the C isozyme. J Biol Chem. 1974 Apr 25;249(8):2329-37.
4621826	Liljas A, Kannan KK, Bergsten PC, Waara I, Fridborg K, Strandberg B, Carlbom U, Jarup L, Lovgren S, Petef M: Crystal structure of human carbonic anhydrase C. Nat New Biol. 1972 Feb 2;235(57):131-7.
6407977	Jones GL, Shaw DC: A chemical and enzymological comparison of the common major human erythrocyte carbonic anhydrase II, its minor component, and a new genetic variant, CA II Melbourne (237 Pro leads to His). Hum Genet. 1983;63(4):392-9.
6817747	Jones GL, Sofro AS, Shaw DC: Chemical and enzymological characterization of an Indonesian variant of human erythrocyte carbonic anhydrase II, CAII Jogjakarta (17 Lys leads to Glu). Biochem Genet. 1982 Oct;20(9-10):979-1000.
823150	Henderson LE, Henriksson D, Nyman PO: Primary structure of human carbonic anhydrase C. J Biol Chem. 1976 Sep 25;251(18):5457-63.
8834238	Soda H, Yukizane S, Yoshida I, Koga Y, Aramaki S, Kato H: A point mutation in exon 3 (His 107-->Tyr) in two unrelated Japanese patients with carbonic anhydrase II deficiency with central nervous system involvement. Hum Genet. 1996 Apr;97(4):435-7.
9143915	Hu PY, Lim EJ, Ciccolella J, Strisciuglio P, Sly WS: Seven novel mutations in carbonic anhydrase II deficiency syndrome identified by SSCP and direct sequencing analysis. Hum Mutat. 1997;9(5):383-7.
9541386	Stams T, Chen Y, Boriack-Sjodin PA, Hurt JD, Liao J, May JA, Dean T, Laipis P, Silverman DN, Christianson DW: Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Protein Sci. 1998 Mar;7(3):556-63.

# Drug_Target_3_HGNC_ID:
HGNC:1373

# Drug_Target_3_HPRD_ID:
02023

# Drug_Target_3_ID:
357

# Drug_Target_3_Locus:
8q22

# Drug_Target_3_Molecular_Weight:
29115

# Drug_Target_3_Name:
Carbonic anhydrase 2

# Drug_Target_3_Number_of_Residues:
259

# Drug_Target_3_PDB_ID:
1T9N

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00194	Carb_anhydrase

# Drug_Target_3_Protein_Sequence:
>Carbonic anhydrase 2
SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILN
NGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLV
HWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPR
GLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMV
DNWRPAQPLKNRQIKASFK

# Drug_Target_3_Reaction:
H2CO3 = CO2 + H2O

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Reversible hydration of carbon dioxide

# Drug_Target_3_SwissProt_ID:
P00918

# Drug_Target_3_SwissProt_Name:
CAH2_HUMAN

# Drug_Target_3_Synonyms:
CA-II
Carbonate dehydratase II
Carbonic anhydrase C
Carbonic anhydrase II
EC 4.2.1.1

# Drug_Target_3_Theoretical_pI:
7.47

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
12086984	Lawrence CL, Rainbow RD, Davies NW, Standen NB: Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels. Br J Pharmacol. 2002 Jul;136(5):746-52.
17281115	Guo W, Chen N, Chen Y, Xia Q, Shen Y: Activation of Mitochondrial ATP-Sensitive Potassium Channel Contributes to Protective Effect in Prolonged Myocardial Preservation. Conf Proc IEEE Eng Med Biol Soc. 2005;4:4027-30.
17287451	Comelli M, Metelli G, Mavelli I: Downmodulation of mitochondrial F0F1 ATP synthase by diazoxide in cardiac myoblasts: a dual effect of the drug. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H820-9.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
ATP1A1

# Drug_Target_4_GenBank_ID_Gene:
D00099

# Drug_Target_4_GenBank_ID_Protein:
219942

# Drug_Target_4_GeneCard_ID:
ATP1A1

# Drug_Target_4_Gene_Name:
ATP1A1

# Drug_Target_4_Gene_Sequence:
>3072 bp
ATGGGGAAGGGGGTTGGACGTGATAAGTATGAGCCTGCAGCTGTTTCAGAACAAGGTGAT
AAAAAGGGCAAAAAGGGCAAAAAAGACAGGGACATGGATGAACTGAAGAAAGAAGTTTCT
ATGGATGATCATAAACTTAGCCTTGATGAACTTCATCGTAAATATGGAACAGACTTGAGC
CGGGGATTAACATCTGCTCGTGCAGCTGAGATCCTGGCGCGAGATGGTCCCAACGCCCTC
ACTCCCCCTCCCACTACTCCTGAATGGATCAAGTTTTGTCGGCAGCTCTTTGGGGGGTTC
TCAATGTTACTGTGGATTGGAGCGATTCTTTGTTTCTTGGCTTATAGCATCCAAGCTGCT
ACAGAAGAGGAACCTCAAAACGATAATCTGTACCTGGGTGTGGTGCTATCAGCCGTTGTA
ATCATAACTGGTTGCTTCTCCTACTATCAAGAAGCTAAAAGTTCAAAGATCATGGAATCC
TTCAAAAACATGGTCCCTCAGCAAGCCCTTGTGATTCGAAATGGTGAGAAAATGAGCATA
AATGCGGAGGAAGTTGTGGTTGGGGATCTGGTGGAAGTAAAAGGAGGAGACCGAATTCCT
GCTGACCTCAGAATCATATCTGCAAATGGCTGCAAGGTGGATAACTCCTCGCTCACTGGT
GAATCAGAACCCCAGACTAGGTCTCCAGATTTCACAAATGAAAACCCCCTGGAGACGAGG
AACATTGCCTTCTTTTCAACAAATTGTGTTGAAGGCACCGCACGTGGTATTGTTGTCTAC
ACTGGGGATCGCACTGTGATGGGAAGAATTGCCACACTTGCTTCTGGGCTGGAAGGAGGC
CAGACCCCCATTGCTGCAGAAATTGAACATTTTATCCACATCATCACGGGTGTGGCTGTG
TTCCTGGGTGTGTCTTTCTTCATCCTTTCTCTCATCCTTGAGTACACCTGGCTTGAGGCT
GTCATCTTCCTCATCGGTATCATCGTAGCCAATGTGCCGGAAGGTTTGCTGGCCACTGTC
ACGGTCTGTCTGACACTTACTGCCAAACGCATGGCAAGGAAAAACTGCTTAGTGAAGAAC
TTAGAAGCTGTGGAGACCTTGGGGTCCACGTCCACCATCTGCTCTGATAAAACTGGAACT
CTGACTCAGAACCGGATGACAGTGGCCCACATGTGGTTTGACAATCAAATCCATGAAGCT
GATACGACAGAGAATCAGAGTGGTGTCTCTTTTGACAAGACTTCAGCTACCTGGCTTGCT
CTGTCCAGAATTGCAGGTCTTTGTAACAGGGCAGTGTTTCAGGCTAACCAGGAAAACCTA
CCTATTCTTAAGCGGGCAGTTGCAGGAGATGCCTCTGAGTCAGCACTCTTAAAGTGCATA
GAGCTGTGCTGTGGTTCCGTGAAGGAGATGAGAGAAAGATACGCCAAAATCGTCGAGATA
CCCTTCAACTCCACCAACAAGTACCAGTTGTCTATTCATAAGAACCCCAACACATCGGAG
CCCCAACACCTGTTGGTGATGAAGGGCGCCCCAGAAAGGATCCTAGACCGTTGCAGCTCT
ATCCTCCTCCACGGCAAGGAGCAGCCCCTGGATGAGGAGCTGAAAGACGCCTTTCAGAAC
GCCTATTTGGAGCTGGGGGGCCTCGGAGAACGAGTCCTAGGTTTCTGCCACCTCTTTCTG
CCAGATGAACAGTTTCCTGAAGGGTTCCAGTTTGACACTGACGATGTGAATTTCCCTATC
GATAATCTGTGCTTTGTTGGGCTCATCTCCATGATTGACCCTCCACGGGCGGCCGTTCCT
GATGCCGTGGGCAAATGTCGAAGTGCTGGAATTAAGGTCATCATGGTCACAGGAGACCAT
CCAATCACAGCTAAAGCTATTGCCAAAGGTGTGGGCATCATCTCAGAAGGCAATGAGACC
GTGGAAGACATTGCTGCCCGCCTCAACATCCCAGTCAGCCAGGTGAACCCCAGGGATGCC
AAGGCCTGCGTAGTACACGGCAGTGATCTAAAGGACATGACCTCCGAGCAGCTGGATGAC
ATTTTGAAGTACCACACTGAGATAGTGTTTGCCAGGACCTCCCCTCAGCAGAAGCTCATC
ATTGTGGAAGGCTGCCAAAGACAGGGTGCTATCGTGGCTGTGACTGGTGACGGTGTGAAT
GACTCTCCAGCTTTGAAGAAAGCAGACATTGGGGTTGCTATGGGGATTGCTGGCTCAGAT
GTGTCCAAGCAAGCTGCTGACATGATTCTTCTGGATGACAACTTTGCCTCAATTGTGACT
GGAGTAGAGGAAGGTCGTCTGATCTTTGATAACTTGAAGAAATCCATTGCTTATACCTTA
ACCAGTAACATTCCCGAGATCACCCCGTTCCTGATATTTATTATTGCAAACATTCCACTA
CCACTGGGGACTGTCACCATCCTCTGCATTGACTTGGGCACTGACATGGTTCCTGCCATC
TCCCTGGCTTATGAGCAGGCTGAGAGTGACATCATGAAGAGACAGCCCAGAAATCCCAAA
ACAGACAAACTTGTGAATGAGCGGCTGATCAGCATGGCCTATGGGCAGATTGGAATGATC
CAGGCCCTGGGAGGCTTCTTTACTTACTTTGTGATTCTGGCTGAGAACGGCTTCCTCCCA
ATTCACCTGTTGGGCCTCCGAGTGGACTGGGATGACCGCTGGATCAACGATGTGGAAGAC
AGCTACGGGCAGCAGTGGACCTATGAGCAGAGGAAAATCGTGGAGTTCACCTGCCACACA
GCCTTCTTCGTCAGTATCGTGGTGGTGCAGTGGGCCGACTTGGTCATCTGTAAGACCAGG
AGGAATTCGGTCTTCCAGCAGGGGATGAAGAACAAGATCTTGATATTTGGCCTCTTTGAA
GAGACAGCCCTGGCTGCTTTCCTTTCCTACTGCCCTGGAATGGGTGTTGCTCTTAGGATG
TATCCCCTCAAACCTACCTGGTGGTTCTGTGCCTTCCCCTACTCTCTTCTCATCTTCGTA
TATGACGAAGTCAGAAAACTCATCATCAGGCGACGCCCTGGCGGCTGGGTGGAGAAGGAA
ACCTACTATTAG

# Drug_Target_4_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_4_General_References:
1970326	Shull MM, Pugh DG, Lingrel JB: The human Na, K-ATPase alpha 1 gene: characterization of the 5'-flanking region and identification of a restriction fragment length polymorphism. Genomics. 1990 Mar;6(3):451-60.
2430951	Kawakami K, Ohta T, Nojima H, Nagano K: Primary structure of the alpha-subunit of human Na,K-ATPase deduced from cDNA sequence. J Biochem (Tokyo). 1986 Aug;100(2):389-97.
2891135	Chehab FF, Kan YW, Law ML, Hartz J, Kao FT, Blostein R: Human placental Na+,K+-ATPase alpha subunit: cDNA cloning, tissue expression, DNA polymorphism, and chromosomal localization. Proc Natl Acad Sci U S A. 1987 Nov;84(22):7901-5.
3035563	Shull MM, Lingrel JB: Multiple genes encode the human Na+,K+-ATPase catalytic subunit. Proc Natl Acad Sci U S A. 1987 Jun;84(12):4039-43.
3036582	Sverdlov ED, Monastyrskaya GS, Broude NE, Ushkaryov YuA, Allikmets RL, Melkov AM, Smirnov YuV, Malyshev IV, Dulobova IE, Petrukhin KE, et al.: The family of human Na+,K+-ATPase genes. No less than five genes and/or pseudogenes related to the alpha-subunit. FEBS Lett. 1987 Jun 15;217(2):275-8.
7536695	Ruiz A, Bhat SP, Bok D: Characterization and quantification of full-length and truncated Na,K-ATPase alpha 1 and beta 1 RNA transcripts expressed in human retinal pigment epithelium. Gene. 1995 Apr 3;155(2):179-84.

# Drug_Target_4_HGNC_ID:
HGNC:799

# Drug_Target_4_HPRD_ID:
01662

# Drug_Target_4_ID:
806

# Drug_Target_4_Locus:
1p21

# Drug_Target_4_Molecular_Weight:
112897

# Drug_Target_4_Name:
Sodium/potassium-transporting ATPase alpha-1 chain

# Drug_Target_4_Number_of_Residues:
1023

# Drug_Target_4_PDB_ID:
1MO8

# Drug_Target_4_Pathway:
Amiloride Pathway	SMP00133
Benazepril Pathway	SMP00145
Bendroflumethiazide Pathway	SMP00090
Benzocaine Pathway	SMP00392
Bumetanide Pathway	SMP00088
Bupivacaine Pathway	SMP00393
Captopril Pathway	SMP00146
Chloroprocaine Pathway	SMP00394
Chlorothiazide Pathway	SMP00078
Chlorthalidone Pathway	SMP00122
Cilazapril Pathway	SMP00147
Cocaine Pathway	SMP00395
Cyclothiazide Pathway	SMP00103
Dibucaine Pathway	SMP00396
Diltiazem Pathway	SMP00359
Disopyramide Pathway	SMP00325
Enalapril Pathway	SMP00148
Eplerenone Pathway	SMP00135
Ethacrynic Acid pathway	SMP00097
Flecainide Pathway	SMP00331
Fosinopril Pathway	SMP00149
Fosphenytoin (Antiarrhythmic) Pathway	SMP00326
Furosemide Pathway	SMP00115
Hydrochlorothiazide Pathway	SMP00100
Hydroflumethiazide Pathway	SMP00108
Ibutilide Pathway	SMP00332
Indapamide Pathway	SMP00110
Levobupivacaine Pathway	SMP00397
Lidocaine (Antiarrhythmic) Pathway	SMP00328
Lidocaine (Local Anaesthetic) Pathway	SMP00398
Lisinopril Pathway	SMP00150
Mepivacaine Pathway	SMP00399
Methyclothiazide Pathway	SMP00081
Metolazone Pathway	SMP00105
Mexiletine Pathway	SMP00329
Moexipril Pathway	SMP00151
Oxybuprocaine Pathway	SMP00400
Perindopril Pathway	SMP00152
Phenytoin (Antiarrhythmic) Pathway	SMP00327
Polythiazide Pathway	SMP00080
Prilocaine Pathway	SMP00401
Procainamide (Antiarrhythmic) Pathway	SMP00324
Procaine Pathway	SMP00402
Proparacaine Pathway	SMP00403
Quinapril Pathway	SMP00153
Quinethazone Pathway	SMP00091
Quinidine Pathway	SMP00323
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Ropivacaine Pathway	SMP00404
Spirapril Pathway	SMP00156
Spironolactone Pathway	SMP00134
Tocainide Pathway	SMP00330
Torsemide Pathway	SMP00118
Trandolapril Pathway	SMP00157
Triamterene Pathway	SMP00132
Trichlormethiazide Pathway	SMP00121
Verapamil Pathway	SMP00375

# Drug_Target_4_Pfam_Domain_Function:
PF00122	E1-E2_ATPase
PF00689	Cation_ATPase_C
PF00690	Cation_ATPase_N
PF00702	Hydrolase

# Drug_Target_4_Protein_Sequence:
>Sodium/potassium-transporting ATPase alpha-1 chain precursor
MGKGVGRDKYEPAAVSEQGDKKGKKGKKDRDMDELKKEVSMDDHKLSLDELHRKYGTDLS
RGLTSARAAEILARDGPNALTPPPTTPEWIKFCRQLFGGFSMLLWIGAILCFLAYSIQAA
TEEEPQNDNLYLGVVLSAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIRNGEKMSI
NAEEVVVGDLVEVKGGDRIPADLRIISANGCKVDNSSLTGESEPQTRSPDFTNENPLETR
NIAFFSTNCVEGTARGIVVYTGDRTVMGRIATLASGLEGGQTPIAAEIEHFIHIITGVAV
FLGVSFFILSLILEYTWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKN
LEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTENQSGVSFDKTSATWLA
LSRIAGLCNRAVFQANQENLPILKRAVAGDASESALLKCIELCCGSVKEMRERYAKIVEI
PFNSTNKYQLSIHKNPNTSEPQHLLVMKGAPERILDRCSSILLHGKEQPLDEELKDAFQN
AYLELGGLGERVLGFCHLFLPDEQFPEGFQFDTDDVNFPIDNLCFVGLISMIDPPRAAVP
DAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPRDA
KACVVHGSDLKDMTSEQLDDILKYHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVN
DSPALKKADIGVAMGIAGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTL
TSNIPEITPFLIFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEQAESDIMKRQPRNPK
TDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPIHLLGLRVDWDDRWINDVED
SYGQQWTYEQRKIVEFTCHTAFFVSIVVVQWADLVICKTRRNSVFQQGMKNKILIFGLFE
ETALAAFLSYCPGMGVALRMYPLKPTWWFCAFPYSLLIFVYDEVRKLIIRRRPGGWVEKE
TYY

# Drug_Target_4_Reaction:
ATP + H2O + Na+in + K+out = ADP + phosphate + Na+out + K+in

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients

# Drug_Target_4_SwissProt_ID:
P05023

# Drug_Target_4_SwissProt_Name:
AT1A1_HUMAN

# Drug_Target_4_Synonyms:
EC 3.6.3.9
Na(+)/K(+) ATPase alpha-1 subunit
Sodium pump subunit alpha 1
Sodium/potassium-transporting ATPase alpha-1 chain precursor

# Drug_Target_4_Theoretical_pI:
5.15

# Drug_Target_4_Transmembrane_Regions:
88-108
132-152
289-308
321-338
773-792
803-823
844-866
919-938
952-970
986-1006

# Drug_Target_5_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
12726817	O'Malley D, Shanley LJ, Harvey J: Insulin inhibits rat hippocampal neurones via activation of ATP-sensitive K+ and large conductance Ca2+-activated K+ channels. Neuropharmacology. 2003 Jun;44(7):855-63.
16446048	Zhang L, Li X, Zhou R, Xing G: Possible role of potassium channel, big K in etiology of schizophrenia. Med Hypotheses. 2006;67(1):41-3. Epub 2006 Jan 30.
2541731	Klockner U, Trieschmann U, Isenberg G: Pharmacological modulation of calcium and potassium channels in isolated vascular smooth muscle cells. Arzneimittelforschung. 1989 Jan;39(1A):120-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
KCNMA1

# Drug_Target_5_GenBank_ID_Gene:
U13913

# Drug_Target_5_GenBank_ID_Protein:
537439

# Drug_Target_5_GeneCard_ID:
KCNMA1

# Drug_Target_5_Gene_Name:
KCNMA1

# Drug_Target_5_Gene_Sequence:
>3639 bp
ATGAGTAGCAATATCCACGCGAACCATCTCAGCCTAGACGCGTCCTCCTCCTCCTCCTCC
TCCTCTTCCTCTTCTTCTTCTTCCTCCTCCTCTTCCTCCTCGTCCTCGGTCCACGAGCCC
AAGATGGATGCGCTCATCATCCCGGTGACCATGGAGGTGCCGTGCGACAGCCGGGGCCAA
CGCATGTGGTGGGCTTTCCTGGCCTCCTCCATGGTGACTTTCTTCGGGGGCCTCTTCATC
ATCTTGCTCTGGCGGACGCTCAAGTACCTGTGGACCGTGTGCTGCCACTGCGGGGGCAAG
ACGAAGGAGGCCCAGAAGATTAACAATGGCTCAAGCCAGGCGGATGGCACTCTCAAACCA
GTGGATGAAAAAGAGGAGGCAGTGGCCGCCGAGGTCGGCTGGATGACCTCCGTGAAGGAC
TGGGCGGGGGTGATGATATCCGCCCAGACACTGACTGGCAGAGTCCTGGTTGTCTTAGTC
TTTGCTCTCAGCATCGGTGCACTTGTAATATACTTCATAGATTCATCAAACCCAATAGAA
TCCTGCCAGAATTTCTACAAAGATTTCACATTACAGATCGACATGGCTTTCAACGTGTTC
TTCCTTCTCTACTTCGGCTTGCGGTTTATTGCAGCCAACGATAAATTGTGGTTCTGGCTG
GAAGTGAACTCTGTAGTGGATTTCTTCACGGTGCCCCCCGTGTTTGTGTCTGTGTACTTA
AACAGAAGTTGGCTTGGTTTGAGATTTTTAAGAGCTCTGAGACTGATACAGTTTTCAGAA
ATTTTGCAGTTTCTGAATATTCTTAAAACAAGTAATTCCATCAAGCTGGTGAATCTGCTC
TCCATATTTATCAGCACGTGGCTGACTGCAGCCGGGTTCATCCATTTGGTGGAGAATTCA
GGGGACCCATGGGAAAATTTCCAAAACAACCAGGCTCTCACCTACTGGGAATGTGTCTAT
TTACTCATGGTCACAATGTCCACCGTTGGTTATGGGGATGTTTATGCAAAAACCACACTT
GGGCGCCTCTTCATGGTCTTCTTCATCCTCGGGGGACTGGCCATGTTTGCCAGCTACGTC
CCTGAAATCATAGAGTTAATAGGAAACCGCAAGAAATACGGGGGCTCCTATAGTGCGGTT
AGTGGAAGAAAGCACATTGTGGTCTGCGGACACATCACTCTGGAGAGTGTTTCCAACTTC
CTGAAGGACTTTCTGCACAAGGACCGGGATGACGTCAATGTGGAGATCGTTTTTCTTCAC
AACATCTCCCCCAACCTGGAGCTTGAAGCTCTGTTCAAACGACATTTTACTCAGGTGGAA
TTTTATCAGGGTTCCGTCCTCAATCCACATGATCTTGCAAGAGTCAAGATAGAGTCAGCA
GATGCATGCCTGATCCTTGCCAACAAGTACTGCGCTGACCCGGATGCGGAGGATGCCTCG
AATATCATGAGAGTAATCTCCATAAAGAACTACCATCCGAAGATAAGAATCATCACTCAA
ATGCTGCAGTATCACAACAAGGCCCATCTGCTAAACATCCCGAGCTGGAATTGGAAAGAA
GGTGATGACGCAATCTGCCTCGCAGAGTTGAAGTTGGGCTTCATAGCCCAGAGCTGCCTG
GCTCAAGGCCTCTCCACCATGCTTGCCAACCTCTTCTCCATGAGGTCATTCATAAAGATT
GAGGAAGACACATGGCAGAAATACTACTTGGAAGGAGTCTCAAATGAAATGTACACAGAA
TATCTCTCCAGTGCCTTCGTGGGTCTGTCCTTCCCTACTGTTTGTGAGCTGTGTTTTGTG
AAGCTCAAGCTCCTAATGATAGCCATTGAGTACAAGTCTGCCAACCGAGAGAGCCGTATA
TTAATTAATCCTGGAAACCATCTTAAGATCCAAGAAGGTACTTTAGGATTTTTCATCGCA
AGTGATGCCAAAGAAGTTAAAAGGGCATTTTTTTACTGCAAGGCCTGTCATGATGACATC
ACAGATCCCAAAAGAATAAAAAAATGTGGCTGCAAACGGCCCAAGATGTCCATCTACAAG
AGAATGAGACGGGCATGTTGTTTTGATTGCGGACGTTCTGAGCGTGACTGCTCATGCATG
TCAGGCCGTGTGCGTGGTAACGTGGACACCCTTGAGAGAGCCTTCCCACTTTCTTCTGTC
TCTGTTAATGATTGCTCCACCAGTTTCCGTGCCTTTGAAGATGAGCAGCCGTCAACACTA
TCACCAAAAAAAAAGCAACGGAATGGAGGCATGCGGAACTCACCCAACACCTCGCCTAAG
CTGATGAGGCATGACCCCTTGTTAATTCCTGGCAATGATCAGATTGACAACATGGACTCC
AATGTGAAGAAGTACGACTCTACTGGGATGTTTCACTGGTGTGCACCCAAGGAGATAGAG
AAAGTCATCCTGACTCGAAGTGAAGCTGCCATGACCGTCCTGAGTGGCCATGTCGTGGTC
TGCATCTTTGGCGACGTCAGCTCAGCCCTGATCGGCCTCCGGAACCTGGTGATGCCGCTC
CGTGCCAGCAACTTTCATTACCATGAGCTCAAGCACATTGTGTTTGTGGGCTCTATTGAG
TACCTCAAGCGGGAATGGGAGACGCTTCATAACTTCCCCAAAGTGTCCATATTGCCTGGT
ACGCCATTAAGTCGGGCTGATTTAAGGGCTGTCAACATCAACCTCTGTGACATGTGCGTT
ATCCTGTCAGCCAATCAGAATAATATTGATGATACTTCGCTGCAGGACAAGGAATGCATC
TTGGCGTCACTCAACATCAAATCTATGCAGTTTGATGACAGCATCGGAGTCTTGCAGGCT
AATTCCCAAGGGTTCACACCTCCAGGAATGGATAGATCCTCTCCAGATAACAGCCCAGTG
CACGGGATGTTACGTCAACCATCCATCACAACTGGGGTCAACATCCCCATCATCACTGAA
CTAGTGAACGATACTAATGTTCAGTTTTTGGACCAAGACGATGATGATGACCCTGATACA
GAACTGTACCTCACGCAGCCCTTTGCCTGTGGGACAGCATTTGCCGTCAGTGTCCTGGAC
TCACTCATGAGCGCGACGTACTTCAATGACAATATCCTCACCCTGATACGGACCCTGGTG
ACCGGAGGAGCCACGCCGGAGCTGGAGGCTCTGATTGCTGAGGAAAACGCCCTTAGAGGT
GGCTACAGCACCCCGCAGACACTGGCCAATAGGGACCGCTGCCGCGTGGCCCAGTTAGCT
CTGCTCGATGGGCCATTTGCGGACTTAGGGGATGGTGGTTGTTATGGTGATCTGTTCTGC
AAAGCTCTGAAAACATATAATATGCTTTGTTTTGGAATTTACCGGCTGAGAGATGCTCAC
CTCAGCACCCCCAGTCAGTGCACAAAGAGGTATGTCATCACCAACCCGCCCTATGAGTTT
GAGCTCGTGCCGACGGACCTGATCTTCTGCTTAATGCAGTTTGACCACAATGCCGGCCAG
TCCCGGGCCAGCCTGTCCCATTCCTCCCACTCGTCGCAGTCCTCCAGCAAGAAGAGCTCC
TCTGTTCACTCCATCCCATCCACAGCAAACCGACAGAACCGGCCCAAGTCCAGGGAGTCC
CGGGACAAACAGAAGTACGTGCAGGAAGAGCGGCTTTGA

# Drug_Target_5_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_5_General_References:
10097176	Wallner M, Meera P, Toro L: Molecular basis of fast inactivation in voltage and Ca2+-activated K+ channels: a transmembrane beta-subunit homolog. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4137-42.
10692449	Brenner R, Jegla TJ, Wickenden A, Liu Y, Aldrich RW: Cloning and functional characterization of novel large conductance calcium-activated potassium channel beta subunits, hKCNMB3 and hKCNMB4. J Biol Chem. 2000 Mar 3;275(9):6453-61.
7573516	McCobb DP, Fowler NL, Featherstone T, Lingle CJ, Saito M, Krause JE, Salkoff L: A human calcium-activated potassium channel gene expressed in vascular smooth muscle. Am J Physiol. 1995 Sep;269(3 Pt 2):H767-77.
7877450	Dworetzky SI, Trojnacki JT, Gribkoff VK: Cloning and expression of a human large-conductance calcium-activated potassium channel. Brain Res Mol Brain Res. 1994 Nov;27(1):189-93.
7987297	Pallanck L, Ganetzky B: Cloning and characterization of human and mouse homologs of the Drosophila calcium-activated potassium channel gene, slowpoke. Hum Mol Genet. 1994 Aug;3(8):1239-43.
7993625	Tseng-Crank J, Foster CD, Krause JD, Mertz R, Godinot N, DiChiara TJ, Reinhart PH: Cloning, expression, and distribution of functionally distinct Ca(2+)-activated K+ channel isoforms from human brain. Neuron. 1994 Dec;13(6):1315-30.
8821792	Wallner M, Meera P, Ottolia M, Kaczorowski GJ, Latorre R, Garcia ML, Stefani E, Toro L: Characterization of and modulation by a beta-subunit of a human maxi KCa channel cloned from myometrium. Receptors Channels. 1995;3(3):185-99.
8962157	Wallner M, Meera P, Toro L: Determinant for beta-subunit regulation in high-conductance voltage-activated and Ca(2+)-sensitive K+ channels: an additional transmembrane region at the N terminus. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14922-7.
9391153	Meera P, Wallner M, Song M, Toro L: Large conductance voltage- and calcium-dependent K+ channel, a distinct member of voltage-dependent ion channels with seven N-terminal transmembrane segments (S0-S6), an extracellular N terminus, and an intracellular (S9-S10) C terminus. Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14066-71.

# Drug_Target_5_HGNC_ID:
HGNC:6284

# Drug_Target_5_HPRD_ID:
15967

# Drug_Target_5_ID:
610

# Drug_Target_5_Locus:
10q22.3

# Drug_Target_5_Molecular_Weight:
137561

# Drug_Target_5_Name:
Calcium-activated potassium channel subunit alpha 1

# Drug_Target_5_Number_of_Residues:
1236

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00520	Ion_trans
PF03493	BK_channel_a

# Drug_Target_5_Protein_Sequence:
>Calcium-activated potassium channel subunit alpha 1
MANGGGGGGGSSGGGGGGGGSSLRMSSNIHANHLSLDASSSSSSSSSSSSSSSSSSSSSS
VHEPKMDALIIPVTMEVPCDSRGQRMWWAFLASSMVTFFGGLFIILLWRTLKYLWTVCCH
CGGKTKEAQKINNGSSQADGTLKPVDEKEEAVAAEVGWMTSVKDWAGVMISAQTLTGRVL
VVLVFALSIGALVIYFIDSSNPIESCQNFYKDFTLQIDMAFNVFFLLYFGLRFIAANDKL
WFWLEVNSVVDFFTVPPVFVSVYLNRSWLGLRFLRALRLIQFSEILQFLNILKTSNSIKL
VNLLSIFISTWLTAAGFIHLVENSGDPWENFQNNQALTYWECVYLLMVTMSTVGYGDVYA
KTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRKKYGGSYSAVSGRKHIVVCGHITLES
VSNFLKDFLHKDRDDVNVEIVFLHNISPNLELEALFKRHFTQVEFYQGSVLNPHDLARVK
IESADACLILANKYCADPDAEDASNIMRVISIKNYHPKIRIITQMLQYHNKAHLLNIPSW
NWKEGDDAICLAELKLGFIAQSCLAQGLSTMLANLFSMRSFIKIEEDTWQKYYLEGVSNE
MYTEYLSSAFVGLSFPTVCELCFVKLKLLMIAIEYKSANRESRILINPGNHLKIQEGTLG
FFIASDAKEVKRAFFYCKACHDDITDPKRIKKCGCKRPKMSIYKRMRRACCFDCGRSERD
CSCMSGRVRGNVDTLERAFPLSSVSVNDCSTSFRAFEDEQPSTLSPKKKQRNGGMRNSPN
TSPKLMRHDPLLIPGNDQIDNMDSNVKKYDSTGMFHWCAPKEIEKVILTRSEAAMTVLSG
HVVVCIFGDVSSALIGLRNLVMPLRASNFHYHELKHIVFVGSIEYLKREWETLHNFPKVS
ILPGTPLSRADLRAVNINLCDMCVILSANQNNIDDTSLQDKECILASLNIKSMQFDDSIG
VLQANSQGFTPPGMDRSSPDNSPVHGMLRQPSITTGVNIPIITELVNDTNVQFLDQDDDD
DPDTELYLTQPFACGTAFAVSVLDSLMSATYFNDNILTLIRTLVTGGATPELEALIAEEN
ALRGGYSTPQTLANRDRCRVAQLALLDGPFADLGDGGCYGDLFCKALKTYNMLCFGIYRL
RDAHLSTPSQCTKRYVITNPPYEFELVPTDLIFCLMQFDHNAGQSRASLSHSSHSSQSSS
KKSSSVHSIPSTANRQNRPKSRESRDKQKYVQEERL

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX)

# Drug_Target_5_SwissProt_ID:
Q12791

# Drug_Target_5_SwissProt_Name:
KCMA1_HUMAN

# Drug_Target_5_Synonyms:
BK channel
BKCA alpha
Calcium-activated potassium channel, subfamily M subunit alpha 1
K(VCA)alpha
KCa1.1
Maxi K channel
MaxiK
Slo homolog
Slo-alpha
Slo1
Slowpoke homolog
hSlo

# Drug_Target_5_Theoretical_pI:
7.07

# Drug_Target_5_Transmembrane_Regions:
87-107
179-199
215-235
240-260
265-285
301-321
368-388

# Drug_Target_6_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
SLC12A3

# Drug_Target_6_GenBank_ID_Gene:
U44128

# Drug_Target_6_GenBank_ID_Protein:
1172161

# Drug_Target_6_GeneCard_ID:
SLC12A3

# Drug_Target_6_Gene_Name:
SLC12A3

# Drug_Target_6_Gene_Sequence:
>3093 bp
ATGGCAGAACTGCCCACAACAGAGACGCCTGGGGACGCCACTTTGTGCAGCGGGCGCTTC
ACCATCAGCACACTGCTGAGCAGTGATGAGCCCTCTCCACCAGCTGCCTATGACAGCAGC
CACCCCAGCCACCTGACCCACAGCAGCACCTTCTGCATGCGCACCTTTGGCTACAACACG
ATCGATGTGGTGCCCACATATGAGCACTATGCCAACAGCACCCAGCCTGGTGAGCCCCGG
AAGGTCCGGCCCACACTGGCTGACCTGCACTCCTTCCTCAAGCAGGAAGGCAGACACCTG
CATGCCCTGGCCTTTGACAGCCGGCCCAGCCACGAGATGACTGATGGGCTGGTGGAGGGC
GAGGCAGGCACCAGCAGCGAGAAGAACCCCGAGGAGCCAGTGCGCTTCGGCTGGGTCAAG
GGGGTGATGATTCGTTGCATGCTCAACATTTGGGGCGTGATCCTCTACCTGCGGCTGCCC
TGGATTACGGCCCAGGCAGGCATCGTCCTGACCTGGATCATCATCCTGCTGTCGGTCACG
GTGACCTCCATCACAGGCCTCTCCATCTCAGCCATCTCCACCAATGGCAAGGTCAAGTCA
GGTGGCACCTACTTCCTCATCTCCCGGAGTCTGGGCCCAGAGCTTGGGGGCTCCATCGGC
CTCATTTTCGCTTTCGCCAATGCCGTGGGTGTGGCCATGCACACGGTGGGCTTTGCAGAG
ACCGTGCGGGACCTGCTCCAGGAGTATGGGGCACCCATCGTGGACCCCATTAACGACATC
CGCATCATTGGCGTGGTCTCGGTCACTGTGCTGCTGGCCATCTCCCTGGCTGGCATGGAG
TGGGAGTCCAAGGCCCAGGTGCTGTTCTTCCTTGTCATCATGGTCTCCTTTGCCAACTAT
TTAGTGGGGACGCTGATCCCCCCATCTGAGGACAAGGCCTCCAAGGGCTTCTTCAGCTAC
CGGGCGGACATTTTTGTCCAGAACTTGGTGCCTGACTGGCGGGGTCCAGATGGCACCTTC
TTCGGAATGTTCTCCATCTTCTTCCCCTCGGCCACAGGCATCCTGGCAGGGGCCAACATA
TCTGGTGACCTCAAGGACCCTGCTATAGCCATCCCCAAGGGGACCCTCATGGCCATTTTC
TGGACGACCATTTCCTACCTGGCCATCTCAGCCACCATTGGCTCCTGCGTGGTGCGTGAT
GCCTCTGGGGTCCTGAATGACACAGTGACCCCTGGCTGGGGTGCCTGCGAGGGGCTGGCC
TGCAGCTATGGCTGGAACTTCACCGAGTGCACCCAGCAGCACAGCTGCCACTACGGCCTC
ATCAACTATTACCAGACCATGAGCATGGTGTCAGGCTTCGCGCCCCTGATCACGGCTGGC
ATCTTCGGGGCCACCCTCTCCTCTGCCCTGGCCTGCCTTGTCTCTGCTGCCAAAGTCTTC
CAGTGCCTTTGCGAGGACCAGCTGTACCCACTGATCGGCTTCTTCGGCAAAGGCTATGGC
AAGAACAAGGAGCCCGTGCGTGGCTACCTGCTGGCCTACGCCATCGCTGTGGCCTTCATC
ATCATCGCTGAGCTCAACACCATAGCCCCCATCATTTCCAACTTCTTCCTCTGCTCCTAT
GCCCTCATCAACTTCAGCTGCTTCCACGCCTCCATCACCAACTCGCCTGGGTGGAGACCT
TCATTCCAATACTACAACAAGTGGGCGGCGCTGTTTGGGGCTATCATCTCCGTGGTCATC
ATGTTCCTCCTCACCTGGTGGGCGGCCCTCATCGCCATTGGCGTGGTGCTCTTCCTCCTG
CTCTATGTCATCTACAAGAAGCCAGAGGTAAATTGGGGCTCCTCGGTACAGGCTGGCTCC
TACAACCTGGCCCTCAGCTACTCGGTGGGCCTCAATGAGGTGGAAGACCACATCAAGAAC
TACCGCCCCCAGTGCCTGGTGCTCACGGGGCCCCCCAACTTCCGCCCGGCCCTGGTGGAC
TTTGTGGGCACCTTCACCCGGAACCTCAGCCTGATGATCTGTGGCCACGTGCTCATCGGA
CCCCACAAGCAGAGGATGCCTGAGCTCCAGCTCATCGCCAACGGGCACACCAAGTGGCTG
AACAAGAGGAAGATCAAGGCCTTCTACTCGGATGTCATTGCCGAGGACCTCCGCAGAGGC
GTCCAGATCCTCATGCAGGCCGCAGGTCTCGGGAGAATGAAGCCCAACATTCTGGTGGTT
GGGTTCAAGAAGAACTGGCAGTCGGCTCACCCGGCCACAGTGGAAGACTACATTGGCATC
CTCCATGATGCCTTTGAGTTCAACTATGGCGTGTGTGTCATGAGGATGCGGGAGGGACTC
AACGTGTCCAAGATGATGCAGGCGCACATTAACCCCGTGTTTGACCCAGCGGAGGACGGG
AAGGAAGCCAGCGCCAGAGGTGCCAGGCCATCAGTCTCTGGCGCTTTGGACCCCAAGGCC
CTGGTGAAGGAGGAGCAGGCCACCACCATCTTCCAGTCGGAGCAGGGCAAGAAGACCATA
GACATCTACTGGCTCTTTGACGATGGAGGCCTCACCCTCCTCATTCCCTATCTCCTTGGC
CGCAAGAGGAGGTGGAGCAAATGCAAGATCCGTGTGTTCGTAGGCGGCCAGATTAACAGG
ATGGACCAGGAGAGAAAGGCGATCATTTCTCTGCTGAGCAAGTTCCGACTGGGATTCCAT
GAAGTCCACATCCTCCCTGACATCAACCAGAACCCTCGGGCTGAGCACACCAAGAGGTTT
GAGGACATGATTGCACCCTTCCGTCTGAATGATGGCTTCAAGGATGAGGCCACTGTCAAC
GAGATGCGGCGGGACTGCCCCTGGAAGATCTCAGATGAGGAGATTACGAAGAACAGAGTC
AAGTCCCTTCGGCAGGTGAGGCTGAATGAGATTGTGCTGGATTACTCCCGAGACGCTGCT
CTCATCGTCATCACTTTGCCCATAGGGAGGAAGGGGAAGTGCCCCAGCTCGCTGTACATG
GCCTGGCTGGAGACCCTGTCCCAGGACCTCAGACCTCCAGTCATCCTGATCCGAGGAAAC
CAGGAAAACGTGCTCACCTTTTACTGCCAGTAA

# Drug_Target_6_General_Function:
Involved in transporter activity

# Drug_Target_6_General_References:
8528245	Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ, Gitleman HJ, Lifton RP: Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. 1996 Jan;12(1):24-30.
8812482	Mastroianni N, De Fusco M, Zollo M, Arrigo G, Zuffardi O, Bettinelli A, Ballabio A, Casari G: Molecular cloning, expression pattern, and chromosomal localization of the human Na-Cl thiazide-sensitive cotransporter (SLC12A3). Genomics. 1996 Aug 1;35(3):486-93.

# Drug_Target_6_HGNC_ID:
HGNC:10912

# Drug_Target_6_HPRD_ID:
02984

# Drug_Target_6_ID:
466

# Drug_Target_6_Locus:
16q13

# Drug_Target_6_Molecular_Weight:
113140

# Drug_Target_6_Name:
Solute carrier family 12 member 3

# Drug_Target_6_Number_of_Residues:
1021

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Bendroflumethiazide Pathway	SMP00090
Chlorothiazide Pathway	SMP00078
Chlorthalidone Pathway	SMP00122
Cyclothiazide Pathway	SMP00103
Hydrochlorothiazide Pathway	SMP00100
Hydroflumethiazide Pathway	SMP00108
Indapamide Pathway	SMP00110
Methyclothiazide Pathway	SMP00081
Metolazone Pathway	SMP00105
Polythiazide Pathway	SMP00080
Quinethazone Pathway	SMP00091
Trichlormethiazide Pathway	SMP00121

# Drug_Target_6_Pfam_Domain_Function:
PF00324	AA_permease
PF08403	AA_permease_N

# Drug_Target_6_Protein_Sequence:
>Solute carrier family 12 member 3
MAELPTTETPGDATLCSGRFTISTLLSSDEPSPPAAYDSSHPSHLTHSSTFCMRTFGYNT
IDVVPTYEHYANSTQPGEPRKVRPTLADLHSFLKQEGRHLHALAFDSRPSHEMTDGLVEG
EAGTSSEKNPEEPVRFGWVKGVMIRCMLNIWGVILYLRLPWITAQAGIVLTWIIILLSVT
VTSITGLSISAISTNGKVKSGGTYFLISRSLGPELGGSIGLIFAFANAVGVAMHTVGFAE
TVRDLLQEYGAPIVDPINDIRIIGVVSVTVLLAISLAGMEWESKAQVLFFLVIMVSFANY
LVGTLIPPSEDKASKGFFSYRADIFVQNLVPDWRGPDGTFFGMFSIFFPSATGILAGANI
SGDLKDPAIAIPKGTLMAIFWTTISYLAISATIGSCVVRDASGVLNDTVTPGWGACEGLA
CSYGWNFTECTQQHSCHYGLINYYQTMSMVSGFAPLITAGIFGATLSSALACLVSAAKVF
QCLCEDQLYPLIGFFGKGYGKNKEPVRGYLLAYAIAVAFIIIAELNTIAPIISNFFLCSY
ALINFSCFHASITNSPGWRPSFQYYNKWAALFGAIISVVIMFLLTWWAALIAIGVVLFLL
LYVIYKKPEVNWGSSVQAGSYNLALSYSVGLNEVEDHIKNYRPQCLVLTGPPNFRPALVD
FVGTFTRNLSLMICGHVLIGPHKQRMPELQLIANGHTKWLNKRKIKAFYSDVIAEDLRRG
VQILMQAAGLGRMKPNILVVGFKKNWQSAHPATVEDYIGILHDAFEFNYGVCVMRMREGL
NVSKMMQAHINPVFDPAEDGKEASARVDPKALVKEEQATTIFQSEQGKKTIDIYWLFDDG
GLTLLIPYLLGRKRRWSKCKIRVFVGGQINRMDQERKAIISLLSKFRLGFHEVHILPDIN
QNPRAEHTKRFEDMIAPFRLNDGFKDEATVNEMRRDCPWKISDEEITKNRVKSLRQVRLN
EIVLDYSRDAALIVITLPIGRKGKCPSSLYMAWLETLSQDLRPPVILIRGNQENVLTFYC
Q

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption

# Drug_Target_6_SwissProt_ID:
P55017

# Drug_Target_6_SwissProt_Name:
S12A3_HUMAN

# Drug_Target_6_Synonyms:
Na-Cl symporter
Thiazide-sensitive sodium-chloride cotransporter

# Drug_Target_6_Theoretical_pI:
7.94

# Drug_Target_6_Transmembrane_Regions:
136-156
159-179
219-239
262-282
287-307
340-360
378-398
453-473
512-532
535-555
578-598
661-681

#END_DRUGCARD DB01119
